Skip to main content

HealthLinx Says Sigma-Aldrich Patent Challenge Is Rejected

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Australian biomarker discovery firm HealthLinx said this week that the European Patent Office has rejected Sigma-Aldrich's objection to a patent issued to HealthLinx covering IgY immunodepletion technology.

The patent at the center of the dispute, EP1540304, is entitled, "Depletion of Plasma Proteins," and covers technology that is used in discovering protein biomarkers.

According to HealthLinx, it has been defending its patent position over the past 18 months. It noted that Sigma-Aldrich has a final opportunity to argue its position in September, but the firm is "confident that no additional material arguments can be presented by Sigma that would alter the EPO's decision."

Melbourne-based HealthLinx also said that it has a patent covering the technology in Australia and has offered Sigma the opportunity to license the technology. However, Sigma chose to withdraw its products that infringe the patent from the Australia market instead, it said.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.